Retatrutide vs. Wegovy: What the Data Actually Shows

The Temptation of Cross-Trial Comparisons

When retatrutide Phase 2 data showed up to 24.2% mean body weight loss at 48 weeks, the immediate question from clinicians and patients alike was: how does this compare to semaglutide 2.4 mg (Wegovy)? The answer requires careful interpretation, because these compounds were studied in different trials, with different patient populations, at different times.

Cross-trial comparisons — sometimes called naive indirect comparisons — are inherently limited. Differences in baseline BMI, demographics, comorbidity profiles, diet and exercise counseling intensity, and even placebo response rates can all influence outcomes. The only definitive way to compare two therapies is a head-to-head randomized controlled trial, which has not been conducted for retatrutide versus semaglutide 2.4 mg.

The Numbers at a Glance

In the STEP 1 trial, semaglutide 2.4 mg produced a mean body weight reduction of approximately 14.9% at 68 weeks in adults with obesity or overweight (BMI ≥ 30, or ≥ 27 with at least one weight-related comorbidity) without diabetes.

In the Phase 2 trial of retatrutide, the highest dose group (12 mg) achieved a mean weight loss of 24.2% at 48 weeks in a similar population of adults with obesity. Notably, this was at a shorter treatment duration, and the weight loss trajectory had not yet plateaued, suggesting that longer treatment could yield further reductions.

These headline figures suggest a meaningful difference in magnitude, but several contextual factors deserve attention.

Mechanism: Triple vs. Single Agonist

Semaglutide is a selective GLP-1 receptor agonist. It reduces appetite, slows gastric emptying, and acts on central nervous system pathways involved in satiety.

Retatrutide is a triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. The addition of glucagon receptor agonism is hypothesized to increase energy expenditure through effects on hepatic metabolism and thermogenesis, while GIP receptor agonism may contribute to enhanced insulin sensitivity and potentially synergistic effects on appetite regulation.

This mechanistic difference is not trivial. Glucagon receptor activation in the context of obesity pharmacotherapy is a relatively novel approach, and its incremental contribution to weight loss beyond GLP-1 and GIP agonism is an active area of investigation.

Population and Trial Design Differences

Several differences between the STEP program and the retatrutide Phase 2 trial complicate direct comparison:

• Trial duration: STEP 1 ran for 68 weeks; the retatrutide Phase 2 trial reported 48-week data. Weight loss with GLP-1 class drugs typically continues beyond 48 weeks, making the retatrutide results at an earlier timepoint particularly notable.
• Baseline characteristics: Mean baseline BMI and body weight differed between trials, which can influence the percentage of weight lost.
• Sample size: STEP 1 enrolled over 1,900 participants. The retatrutide Phase 2 trial included approximately 340 participants across multiple dose groups. Larger Phase 3 trials will provide more robust estimates.
• Lifestyle intervention: Both trials included lifestyle counseling, but the intensity and standardization of these interventions can vary.

Tolerability Considerations

Both agents share GLP-1 receptor agonism, so gastrointestinal side effects — nausea, vomiting, diarrhea, and constipation — are common to both. In the retatrutide Phase 2 trial, GI adverse events were generally mild to moderate and most frequent during dose escalation. Discontinuation rates due to adverse events appeared broadly comparable, but definitive tolerability comparisons require head-to-head data.

What We Still Need

The ongoing Phase 3 program for retatrutide will provide longer-duration, larger-sample data that will better define its efficacy and safety profile. Until a direct comparative trial is conducted, any ranking of these therapies remains provisional.

For clinicians and patients, the key takeaway is that retatrutide’s early data are promising in magnitude, but the evidence base for semaglutide 2.4 mg is substantially more mature. Treatment decisions should ultimately be guided by individual patient characteristics, tolerability, and the full body of evidence available at the time of prescribing.